In 2001, there were a considerable number of market withdrawals, the most high profile of which was the worldwide withdrawal of cerivastatin. Additionally, there were many significant labelling changes throughout the year resulting from safety concerns. In particular, bupropion received a lot of media attention and was subject to a number of safety updates throughout the year.